Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Desensitising Celiac Disease Patients With the Human Hookworm
Celiac Disease
Primary: Duodenal Villus Height:Crypt Depth — 2.73; 2.73 Ratio — p=0.693
N/A N=89,132 Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes
HSV-2 Infection · PreTerm Birth · Pregnancy Complications
Primary: Number of Participants With Preterm Delivery — 100; 83; 247; 5407 Participants
N/A N=87 Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Hookworm Infection
Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
N/A N=12 Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
Hookworm Infection · Allergy
Primary: 100 Mcg/ml Na-ASP-2 Prick-puncture Skin Test — 0 Units on a scale
N/A N=52 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Trachoma
Primary: The Proportion of Communities With C. Trachomatis Infection Prevalence of 1% or Below — 7; 4 community — p=>0.05
N/A N=300 Supplemental Oxygen Reduces Surgical Infection
Wound Infection
Primary: Incisional Surgical Wound Infection — 22; 35 participants — p=0.04
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 3 N=1,676 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Covid19 · Non-specific Effects of Vaccines · Heterologous Immunity
Primary: Acute Infection — 424; 469; 212; 236 Events — p=< 0.05
Phase 3 N=95 Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Central Line-Associated Bloodstream Infection
Primary: Percentage of Therapeutic Failures (Early or Late Failure) in Children and Adolescents With CLABSI Receiving Standard Care Plus Ethanol Lock Therapy (ELT) vs. Standard…
Phase 2 N=15 Enhancement by Poly-ICLC During HIV-1 Infection
HIV-1 Infected Adults With Chronic HIV-1 Infection
Primary: Number Participants With Adverse Events — 11; 3 Participants
Phase 4 N=850 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
HIV Infection
Primary: Cumulative Probability of Death or Unknown Vital Status by Week 24 — 5.2; 5.2 Cumulative probability per 100 persons — p=0.97
Phase 2 N=50 Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
Hepatitis C · HIV
Primary: Percentage of Participants With Achieved SVR12 (HCV RNA <LLOQ 12 Weeks After Completion of Treatment) — 97; 100 percentage of participants
N/A N=73 The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess
Dental Research · Pharmaceutical Preparations, Dental
Primary: Decrease Time of Oral Pain — 9; 9; 5; 4 score on a scale